Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Cardiovascular


Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials

February 16th 2022

Patients with T2D and PAD derived similar relative cardiorenal benefits from canagliflozin treatment but higher absolute benefits compared to those without PAD, with no increase in MALE (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: canagliflozin

Categories: Cardiovascular, Medication, Nephropathy
Tags: canagliflozin

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

February 16th 2022

Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Hepatology, Medication, Nephropathy, News
Tags: Empagliflozin, fibrosis, steatosis

Categories: Cardiovascular, Hepatology, Medication, Nephropathy
Tags: Empagliflozin, fibrosis, steatosis

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

February 16th 2022

Liraglutide had beneficial actions on glycemic parameters and cardiometabolic risk factors in both non-obese and obese patients with T2DM, with a greater efficacy in the latter (Diabetes Therapy)

Categories: Cardiovascular, Medication, News
Tags: liraglutide, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: liraglutide, Type 2 Diabetes

The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury

February 6th 2022

Circulating GIP levels are downregulated in patients with myocardial infarction and following cardiac surgery. These results might suggest nutrition-independent regulation of GIP secretion following myocardial injury in humans (Cardiovascular Diabetology)

Categories: Cardiovascular, News, Pathology

Categories: Cardiovascular, Pathology

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes

February 2nd 2022

SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in primary prevention of MACCE and HF and GLP-1RA for HF. These data call for primary prevention trials using these agents and their combination (Diabetes Care)

Categories: Cardiovascular, Medication, News
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study

January 27th 2022

Our findings suggest protective association of genetically proxied ACE inhibition with diabetes, while genetic proxies for BBs and CCBs possibly relate to an unfavourable metabolic profile (Diabetologia)

Categories: Cardiovascular, Hypertension, Medication, News
Tags: antihypertensives

Categories: Cardiovascular, Hypertension, Medication
Tags: antihypertensives

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors

January 27th 2022

The ESC recently added SGLT2 inhibitors to the management guidelines for HFrEF following good outcomes from DAPA-HF [18] and EMPEROR-Reduced [19] over the last 2 years. We hope that further supporting evidence for SGLT2 inhibitors in the management of HFpEF follows with the results of the ongoing DELIVER trial expected soon, and that as a result similar changes to guidelines may be added to support the use of SGLT2 inhibitors in the management of HFpEF (Diabetes Therapy)

Categories: Cardiovascular, Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: heart failure, SGLT2 inhibitors

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target

January 27th 2022

These findings suggest that HbA1c variability may provide additional information for an optimized management of diabetes, particularly in people within the target of HbA1c (Cardiovascular Diabetology)

Categories: Cardiovascular, Management, Monitoring, News
Tags: HbA1c, Type 2 Diabetes

Categories: Cardiovascular, Management, Monitoring
Tags: HbA1c, Type 2 Diabetes

Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors

January 19th 2022

Our study demonstrated high rates of residual cardio-kidney outcomes and treatment failure in patients with DKD treated with SGLT2is. Patients with high baseline CV risk and the presence of certain conditions, such as atrial fibrillation, PVD, and heart failure, were at higher risk for cardio-kidney events (BMC Medicine)

Categories: Cardiovascular, Nephropathy, News, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Nephropathy, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies

January 18th 2022

Prediabetes was positively associated with risk of all-cause mortality and the incidence of cardiovascular outcomes, CHD, stroke, chronic kidney disease, cancer and dementia (Diabetologia)

Categories: Cardiovascular, Nephropathy, News, Pathology
Tags: prediabetes

Categories: Cardiovascular, Nephropathy, Pathology
Tags: prediabetes

Network meta-analysis on the effects of SGLT2 inhibitors versus finerenone on cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease

December 31st 2021

Given the above limitations of this study, its findings may suggest that among patients with T2D and CKD SGLT2 inhibitors are more effective than finerenone in reducing renal and cardiovascular endpoints, especially renal and cardiac failure events(Frontiers in Pharmacology)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: CKD, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication, Nephropathy
Tags: CKD, SGLT2 inhibitors, Type 2 Diabetes

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

December 17th 2021

Therapy with SGLT-2 inhibitors in patients with cardiometabolic and renal diseases results in a sustained to moderate reduction of the composite CV death or hospitalization for HF, robust reduction of HF and renal outcomes, moderate reduction of CV mortality, total mortality and MACE (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication, Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes

J-curve relationship between long term glycemic control and mortality in diabetic patients with acute myocardial infarction undergoing percutaneous coronary intervention

December 16th 2021

The less strict glycemic control in diabetic patients with AMI would be optimal for preventing mortality, especially in elderly patients (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: glycaemic control, MI

Categories: Cardiovascular
Tags: glycaemic control, MI

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease

December 15th 2021

Empagliflozin reduced the total burden of cardiovascular and hospitalization events in Asian and non-Asian EMPA-REG OUTCOME participants with T2D and established ASCVD, consistent with the overall trial population (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, News
Tags: EMPA-REG OUTCOME, Empagliflozin, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: EMPA-REG OUTCOME, Empagliflozin, Type 2 Diabetes

Association of diabetes with atrial fibrillation types: a systematic review and meta-analysis

December 8th 2021

Our findings suggest that diabetes is associated with an increased likelihood of non-paroxysmal AF rather than paroxysmal AF (Cardiovascular Diabetology)

Categories: Cardiovascular
Tags: AF

Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study

December 8th 2021

Strikingly different metabolic signatures were associated with subclinical coronary atherosclerosis in AA and EA DHS participants (Cardiovascular Diabetology)

Categories: Cardiovascular, News, Screening
Tags: atherosclerosis, metabolomic

Categories: Cardiovascular, Screening
Tags: atherosclerosis, metabolomic

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

December 6th 2021

Empagliflozin thus ameliorates the “cardiac energy-deficient” state, regresses adverse myocardial cellular remodeling, and improves cardiac function, offering therapeutic opportunities to prevent or modulate HF in T2D (Diabetes)

Categories: Cardiovascular, Medication, News
Tags: Empagliflozin, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: Empagliflozin, Type 2 Diabetes

Effect of blood lipid variability on mortality in patients with type 2 diabetes: a large single-center cohort study

November 26th 2021

Blood lipid variability except for triglyceride variability was associated with all-cause and cardiovascular mortality in patients with type 2 diabetes (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: lipid, lipids, Type 2 Diabetes

Categories: Cardiovascular
Tags: lipid, lipids, Type 2 Diabetes

A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study

November 10th 2021

The analysis of data from the LEADER trial demonstrated that higher rates of NSHEs were associated with both a higher risk of severe hypoglycaemia and adverse cardiovascular outcomes in individuals with type 2 diabetes (Diabetologia)

Categories: Cardiovascular, Medication, News, Pathology
Tags: hypoglycemia, LEADER, Type 2 Diabetes

Categories: Cardiovascular, Medication, Pathology
Tags: hypoglycemia, LEADER, Type 2 Diabetes

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence

November 8th 2021

This review intends to expose the probable molecular mechanisms and compile evidence of the synergistic or additive anti-inflammatory effects of SGLT2i and GLP-1RA and their potential impact on the management of patients with obesity and cardiorenal compromise (Journal of Diabetes Research)

Categories: Cardiovascular, Medication, News
Tags: GLP-1RA, glycaemic control, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: GLP-1RA, glycaemic control, SGLT2 inhibitors
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 18
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskNapp DiabetesBoehringer Ingelheim

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors elderly Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership